Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.40 and traded as high as $1.50. Cortexyme shares last traded at $1.41, with a volume of 812,249 shares changing hands.
Cortexyme Stock Performance
The firm has a market capitalization of $42.51 million, a PE ratio of -0.47 and a beta of 1.40. The stock has a fifty day moving average price of $1.58 and a 200-day moving average price of $1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
- Five stocks we like better than Cortexyme
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Dividend Payout Ratio Calculator
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
